 |
 |
This is the agenda for the session on Parkinson's 1:15 p.m. Session 3: Case Study on the Treatment of Parkinson’s Disease Session Objective: The second case study on the use of stem cell therapeutics will focus on the treatment of Parkinson’s Disease and applications to the central nervous system. Among the issues to be addressed through a series a short presentations and panel discussions are the status of and needs of in vitro studies, preclinical steps in animals—including proof of principle, cell toxicity, and human-animal cell chimeras—and proposed clinical trial design—which would include consideration of patient population and the risk:benefit ratio. The committee wishes to thank Fred H. Gage, Salk Institute for Biological Studies, for his help in organizing this session. A clinician’s view on stem cell therapies for Parkinson’s Disease • Olle Lindvall, Professor of Neurology, Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, Lund University Hospital, Sweden Research challenges of stem cell therapeutics • Lorenz Studer, Director, Laboratory of Stem Cell & Tumor Biology, and Associate Member, Memorial Sloan-Kettering Cancer Center Ethical concerns of stem cell therapeutics for Parkinson’s Disease • Lawrence S.B. Goldstein, Howard Hughes Medical Institute Investigator, Professor of Cellular and Molecular Medicine, and Director, UCSD Stem Cell Program, University of California, San Diego ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn